Search 

Albumedix, now part of the life sciences group Sartorius, is an innovation-focused biotechnology company well recognized as a leader in albumin-enabled solutions. With a mission dedicated to better health, over nearly four decades of commitment, Albumedix has supported its partners to deliver safe doses globally, in development, clinical phase and marketed therapeutics, to millions of patients. Albumedix' portfolio of solutions includes the world's only USP-NF-compliant recombinant human albumin (Recombumin®); client-centric services, and proprietary drug-enhancing technology (Veltis®)

Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.

Providing patients with a new way to benefit from Naltrexone

Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.

Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug.  This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.  

The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.

As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.

Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins. 

The NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.

The NIHR:

- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research

- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future

- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services

- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Oppilotech develops first-in-class drugs. We believe that target selection is the most important decision we make in drug discovery – a selective high-quality molecule will never become a drug if it is modulating the wrong target. Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets. We undertake both the target selection and develop the drugs against the identified target. We initially focused our modelling efforts on E.coli identifying several first-in-class antibacterial drug targets and generated active chemical matter against them. The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (e.g. DNA Damage Response) and inflammation.

Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.